logo
Plus   Neg
Share
Email

Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta

Biopharmaceutical company Gilead Sciences Inc. (GILD) announced Sunday that its unit Kite revealed long-term follow-up data from the pivotal ZUMA-1 study of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Yescarta is the first chimeric antigen receptor T or CAR T cell therapy to be approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma or DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for patients with primary central nervous system lymphoma.

Kite, focused on chimeric antigen receptor and T cell receptor engineered cell therapies, noted that with a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

Detailed results were presented at the Annual Meeting of the American Society of Hematology in Atlanta and published in The New England Journal of Medicine.

Sattva Neelapu, ZUMA-1 Co-Lead Investigator, said, "As observed in the SCHOLAR-1 study, treatment options for patients with refractory large B-cell lymphoma have yielded a median overall survival of just six months, with fewer than ten percent of patients achieving complete remission. The durability of response seen with Yescarta in this long-term follow-up reinforces the major advance that CAR T therapy represents for these patients."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Zynga Inc. (ZNGA), a social game developer, Tuesday said it has inked a multi-year deal with Disney to develop and publish a new "Star Wars" mobile game. Shares of Zynga is currently up nearly 8 percent, following the news. As a part of the agreement, Zynga will also assume operation of the live service... Furniture maker La-Z-Boy Inc. (LZB), Tuesday reported a profit and revenues for the first quarter that trounced Wall Street estimates, sending its shares surgtin about 20 percent in after-hours trade. Monroe, Michigan-based La-Z-Boy's first-quarter profit rose to $18.3 million or $0.39 per share from... Shares of Keysight Technologies Inc. (KEYS) are up 12 percent on extended session on Tuesday after the company's earnings and revenues for the third quarter trumped Wall Street expectations and outlook for the current quarter also exceeded estimates. Santa Rosa, California-based Keysight Technologies...
Follow RTT